NASDAQ
PASG

Passage Bio Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Passage Bio Inc Stock Price

Vitals

Today's Low:
$0.7492
Today's High:
$0.7987
Open Price:
$0.75
52W Low:
$0.714
52W High:
$1.92
Prev. Close:
$0.76
Volume:
85551

Company Statistics

Market Cap.:
$42.42 million
Book Value:
2.748
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-24.88%
Return on Equity TTM:
-56.2%

Company Profile

Passage Bio Inc had its IPO on 2020-02-28 under the ticker symbol PASG.

The company operates in the Healthcare sector and Biotechnology industry. Passage Bio Inc has a staff strength of 85 employees.

Stock update

Shares of Passage Bio Inc opened at $0.75 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.75 - $0.8, and closed at $0.76.

This is a +0.13% increase from the previous day's closing price.

A total volume of 85,551 shares were traded at the close of the day’s session.

In the last one week, shares of Passage Bio Inc have slipped by -1.68%.

Passage Bio Inc's Key Ratios

Passage Bio Inc has a market cap of $42.42 million, indicating a price to book ratio of 0.3039 and a price to sales ratio of 0.

In the last 12-months Passage Bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-94310000. The EBITDA ratio measures Passage Bio Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Passage Bio Inc’s operating margin was 0% while its return on assets stood at -24.88% with a return of equity of -56.2%.

In Q2, Passage Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Passage Bio Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Passage Bio Inc’s profitability.

Passage Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7685. Its price to sales ratio in the trailing 12-months stood at 0.

Passage Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$193.70 million
Total Liabilities
$19.87 million
Operating Cash Flow
$13.97 million
Capital Expenditure
$103000
Dividend Payout Ratio
0%

Passage Bio Inc ended 2024 with $193.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $193.70 million while shareholder equity stood at $150.41 million.

Passage Bio Inc ended 2024 with $0 in deferred long-term liabilities, $19.87 million in other current liabilities, 5000.00 in common stock, $-550600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.29 million and cash and short-term investments were $151.48 million. The company’s total short-term debt was $3,326,000 while long-term debt stood at $0.

Passage Bio Inc’s total current assets stands at $153.63 million while long-term investments were $0 and short-term investments were $121.19 million. Its net receivables were $433000.00 compared to accounts payable of $3.38 million and inventory worth $0.

In 2024, Passage Bio Inc's operating cash flow was $13.97 million while its capital expenditure stood at $103000.

Comparatively, Passage Bio Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.76
52-Week High
$1.92
52-Week Low
$0.714
Analyst Target Price
$6.67

Passage Bio Inc stock is currently trading at $0.76 per share. It touched a 52-week high of $1.92 and a 52-week low of $1.92. Analysts tracking the stock have a 12-month average target price of $6.67.

Its 50-day moving average was $0.85 and 200-day moving average was $1.1 The short ratio stood at 1.14 indicating a short percent outstanding of 0%.

Around 896.1% of the company’s stock are held by insiders while 6591.5% are held by institutions.

Frequently Asked Questions About Passage Bio Inc

The stock symbol (also called stock or share ticker) of Passage Bio Inc is PASG

The IPO of Passage Bio Inc took place on 2020-02-28

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$3950
50
+1.28%
$16.73
0.51
+3.14%
$30.5
-0.4
-1.29%
Mirati Ther (MRTX)
$35.13
0.01
+0.03%
$10.75
-0.15
-1.38%
$1.74
0.01
+0.58%
$23.88
-0.38
-1.57%
$92.56
-4.82
-4.95%
$1.71
-0.03
-1.72%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Address

One Commerce Square, Philadelphia, PA, United States, 19103